Clinical significance of p95HER2 Overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies

dc.contributor.author	Serdengecti, S.
dc.contributor.author	Demirelli, F.
dc.contributor.author	Ozguroglu, M.
dc.contributor.author	Turna, H.
dc.contributor.author	Tural, D.
dc.contributor.author	Buyukunal, E.
dc.contributor.author	Ozturk, T.
dc.contributor.author	Ilvan, S.
dc.date.accessioned	2021-03-06T09:44:26Z
dc.date.available	2021-03-06T09:44:26Z
dc.identifier.citation	Tural D., Demirelli F., Serdengecti S., Ozturk T., Ilvan S., Turna H., Ozguroglu M., Buyukunal E., "Clinical significance of p95HER2 Overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies", European Cancer Congress 2013 - 17th ECCO / 38th ESMO / 32nd ESTRO, Amsterdam, Hollanda, 27 Eylül - 01 Ekim 2013, cilt.49
dc.identifier.other	vv_1032021
dc.identifier.other	av_e6efa893-7c66-4465-9e79-42a8a014861a
dc.identifier.uri	http://hdl.handle.net/20.500.12627/151899
dc.language.iso	eng
dc.subject	ONKOLOJİ
dc.subject	Tıp
dc.subject	Klinik Tıp
dc.subject	Onkoloji
dc.subject	İç Hastalıkları
dc.subject	Dahili Tıp Bilimleri
dc.subject	Sağlık Bilimleri
dc.subject	Klinik Tıp (MED)
dc.title	Clinical significance of p95HER2 Overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies
dc.type	Bildiri
dc.contributor.department	İstanbul Üniversitesi , ,
dc.identifier.volume	49
dc.contributor.firstauthorID	142244

Bu öğenin dosyaları:

Dosyalar	Boyut	Biçim	Göster
Bu öğe ile ilişkili dosya yok.